Royalty Pharma PLC Class A

RPRX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
<^LOCK|&HQ>KLOCK|ym!YV@y

Royalty Pharma Earnings: New Growth Drivers Support Durable Royalty Receipts

Royalty Pharma increased its top-line portfolio receipts figure by 6% in the second quarter, partially skewed by a one-time distribution received last year. It lifted 2026 guidance by 2%. Shares traded flat on Aug. 5.

Sponsor Center